

PXD101: A Case History of Histone Deacetylase Inhibitors in Cancer

Nessa Carey

Histone deacetylase inhibitors are progressing through clinical trials for the potential treatment of a broad range of cancers. Using TopoTarget's proprietary small molecule inhibitor PXD101 as a model example, we will examine the rationale behind the use of these agents, their mechanisms of actions and their likely molecular targets, and survey the cancer types and drug combinations that may prove to be therapeutically appropriate. In addition to examining what is known about this class of drugs, we will also be examining the questions that are continuing to intrigue scientists working in this field.